nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—SLC31A1—Carboplatin—bone cancer	0.265	0.522	CbGbCtD
Bortezomib—SLC31A1—Cisplatin—bone cancer	0.227	0.446	CbGbCtD
Bortezomib—CYP3A4—bone cancer	0.216	1	CbGaD
Bortezomib—CYP2C9—Cisplatin—bone cancer	0.00799	0.0157	CbGbCtD
Bortezomib—CYP2D6—Doxorubicin—bone cancer	0.0049	0.00963	CbGbCtD
Bortezomib—CYP3A4—Doxorubicin—bone cancer	0.00311	0.00613	CbGbCtD
Bortezomib—CTSG—connective tissue—bone cancer	0.00117	0.0756	CbGeAlD
Bortezomib—PSMA1—connective tissue—bone cancer	0.00113	0.0726	CbGeAlD
Bortezomib—CTSG—tendon—bone cancer	0.000806	0.052	CbGeAlD
Bortezomib—CTSG—bone marrow—bone cancer	0.000781	0.0504	CbGeAlD
Bortezomib—PSMA1—bone marrow—bone cancer	0.00075	0.0484	CbGeAlD
Bortezomib—PSMD1—tendon—bone cancer	0.00065	0.0419	CbGeAlD
Bortezomib—PSMD1—bone marrow—bone cancer	0.000629	0.0406	CbGeAlD
Bortezomib—PSMB2—connective tissue—bone cancer	0.000627	0.0404	CbGeAlD
Bortezomib—PSMD1—spinal cord—bone cancer	0.000627	0.0404	CbGeAlD
Bortezomib—PSMD2—tendon—bone cancer	0.000576	0.0371	CbGeAlD
Bortezomib—PSMB8—tendon—bone cancer	0.000572	0.0369	CbGeAlD
Bortezomib—PSMD2—bone marrow—bone cancer	0.000558	0.036	CbGeAlD
Bortezomib—PSMD2—spinal cord—bone cancer	0.000555	0.0358	CbGeAlD
Bortezomib—PSMB8—bone marrow—bone cancer	0.000554	0.0357	CbGeAlD
Bortezomib—PSMB5—tendon—bone cancer	0.000505	0.0326	CbGeAlD
Bortezomib—PSMB5—bone marrow—bone cancer	0.00049	0.0316	CbGeAlD
Bortezomib—PSMB5—spinal cord—bone cancer	0.000487	0.0314	CbGeAlD
Bortezomib—PSMB1—tendon—bone cancer	0.000442	0.0285	CbGeAlD
Bortezomib—PSMB2—tendon—bone cancer	0.000431	0.0278	CbGeAlD
Bortezomib—PSMB1—bone marrow—bone cancer	0.000428	0.0276	CbGeAlD
Bortezomib—PSMB1—spinal cord—bone cancer	0.000426	0.0275	CbGeAlD
Bortezomib—PSMB2—bone marrow—bone cancer	0.000417	0.0269	CbGeAlD
Bortezomib—PSMB2—spinal cord—bone cancer	0.000416	0.0268	CbGeAlD
Bortezomib—SLC31A1—tendon—bone cancer	0.000373	0.0241	CbGeAlD
Bortezomib—SLC31A1—bone marrow—bone cancer	0.000362	0.0233	CbGeAlD
Bortezomib—SLC31A1—spinal cord—bone cancer	0.00036	0.0232	CbGeAlD
Bortezomib—PTGS1—connective tissue—bone cancer	0.000162	0.0105	CbGeAlD
Bortezomib—PTGS1—tendon—bone cancer	0.000111	0.00718	CbGeAlD
Bortezomib—PTGS1—spinal cord—bone cancer	0.000107	0.00693	CbGeAlD
Bortezomib—Urethral disorder—Methotrexate—bone cancer	6.78e-05	0.000449	CcSEcCtD
Bortezomib—Weight decreased—Doxorubicin—bone cancer	6.76e-05	0.000448	CcSEcCtD
Bortezomib—Sinusitis—Epirubicin—bone cancer	6.76e-05	0.000448	CcSEcCtD
Bortezomib—Hyperglycaemia—Doxorubicin—bone cancer	6.74e-05	0.000447	CcSEcCtD
Bortezomib—Pneumonia—Doxorubicin—bone cancer	6.71e-05	0.000445	CcSEcCtD
Bortezomib—Infestation NOS—Doxorubicin—bone cancer	6.67e-05	0.000442	CcSEcCtD
Bortezomib—Infestation—Doxorubicin—bone cancer	6.67e-05	0.000442	CcSEcCtD
Bortezomib—Visual impairment—Methotrexate—bone cancer	6.66e-05	0.000442	CcSEcCtD
Bortezomib—Stevens-Johnson syndrome—Doxorubicin—bone cancer	6.61e-05	0.000438	CcSEcCtD
Bortezomib—Hypersensitivity—Cisplatin—bone cancer	6.59e-05	0.000437	CcSEcCtD
Bortezomib—Bradycardia—Epirubicin—bone cancer	6.58e-05	0.000437	CcSEcCtD
Bortezomib—Renal failure—Doxorubicin—bone cancer	6.55e-05	0.000434	CcSEcCtD
Bortezomib—Erythema multiforme—Methotrexate—bone cancer	6.54e-05	0.000433	CcSEcCtD
Bortezomib—Neuropathy peripheral—Doxorubicin—bone cancer	6.54e-05	0.000433	CcSEcCtD
Bortezomib—Haemoglobin—Epirubicin—bone cancer	6.5e-05	0.000431	CcSEcCtD
Bortezomib—Stomatitis—Doxorubicin—bone cancer	6.5e-05	0.000431	CcSEcCtD
Bortezomib—Conjunctivitis—Doxorubicin—bone cancer	6.48e-05	0.00043	CcSEcCtD
Bortezomib—Urinary tract infection—Doxorubicin—bone cancer	6.48e-05	0.00043	CcSEcCtD
Bortezomib—Hepatitis—Epirubicin—bone cancer	6.47e-05	0.000429	CcSEcCtD
Bortezomib—Haemorrhage—Epirubicin—bone cancer	6.47e-05	0.000429	CcSEcCtD
Bortezomib—Eye disorder—Methotrexate—bone cancer	6.46e-05	0.000428	CcSEcCtD
Bortezomib—Tinnitus—Methotrexate—bone cancer	6.44e-05	0.000427	CcSEcCtD
Bortezomib—Hypoaesthesia—Epirubicin—bone cancer	6.44e-05	0.000427	CcSEcCtD
Bortezomib—Asthenia—Cisplatin—bone cancer	6.42e-05	0.000426	CcSEcCtD
Bortezomib—Cardiac disorder—Methotrexate—bone cancer	6.41e-05	0.000425	CcSEcCtD
Bortezomib—Urinary tract disorder—Epirubicin—bone cancer	6.39e-05	0.000423	CcSEcCtD
Bortezomib—Oedema peripheral—Epirubicin—bone cancer	6.37e-05	0.000422	CcSEcCtD
Bortezomib—Haematuria—Doxorubicin—bone cancer	6.36e-05	0.000421	CcSEcCtD
Bortezomib—Connective tissue disorder—Epirubicin—bone cancer	6.36e-05	0.000421	CcSEcCtD
Bortezomib—Urethral disorder—Epirubicin—bone cancer	6.34e-05	0.00042	CcSEcCtD
Bortezomib—Hepatobiliary disease—Doxorubicin—bone cancer	6.31e-05	0.000418	CcSEcCtD
Bortezomib—Epistaxis—Doxorubicin—bone cancer	6.29e-05	0.000417	CcSEcCtD
Bortezomib—Angiopathy—Methotrexate—bone cancer	6.27e-05	0.000416	CcSEcCtD
Bortezomib—Sinusitis—Doxorubicin—bone cancer	6.25e-05	0.000415	CcSEcCtD
Bortezomib—Immune system disorder—Methotrexate—bone cancer	6.24e-05	0.000414	CcSEcCtD
Bortezomib—Visual impairment—Epirubicin—bone cancer	6.23e-05	0.000413	CcSEcCtD
Bortezomib—Mediastinal disorder—Methotrexate—bone cancer	6.23e-05	0.000413	CcSEcCtD
Bortezomib—Chills—Methotrexate—bone cancer	6.2e-05	0.000411	CcSEcCtD
Bortezomib—Diarrhoea—Cisplatin—bone cancer	6.12e-05	0.000406	CcSEcCtD
Bortezomib—Erythema multiforme—Epirubicin—bone cancer	6.12e-05	0.000405	CcSEcCtD
Bortezomib—Bradycardia—Doxorubicin—bone cancer	6.09e-05	0.000404	CcSEcCtD
Bortezomib—Mental disorder—Methotrexate—bone cancer	6.06e-05	0.000401	CcSEcCtD
Bortezomib—Eye disorder—Epirubicin—bone cancer	6.04e-05	0.000401	CcSEcCtD
Bortezomib—Tinnitus—Epirubicin—bone cancer	6.03e-05	0.0004	CcSEcCtD
Bortezomib—Malnutrition—Methotrexate—bone cancer	6.02e-05	0.000399	CcSEcCtD
Bortezomib—Erythema—Methotrexate—bone cancer	6.02e-05	0.000399	CcSEcCtD
Bortezomib—Haemoglobin—Doxorubicin—bone cancer	6.02e-05	0.000399	CcSEcCtD
Bortezomib—Flushing—Epirubicin—bone cancer	6e-05	0.000398	CcSEcCtD
Bortezomib—Cardiac disorder—Epirubicin—bone cancer	6e-05	0.000398	CcSEcCtD
Bortezomib—Hepatitis—Doxorubicin—bone cancer	5.98e-05	0.000397	CcSEcCtD
Bortezomib—Haemorrhage—Doxorubicin—bone cancer	5.98e-05	0.000397	CcSEcCtD
Bortezomib—Hypoaesthesia—Doxorubicin—bone cancer	5.95e-05	0.000395	CcSEcCtD
Bortezomib—Urinary tract disorder—Doxorubicin—bone cancer	5.91e-05	0.000392	CcSEcCtD
Bortezomib—Oedema peripheral—Doxorubicin—bone cancer	5.9e-05	0.000391	CcSEcCtD
Bortezomib—Dysgeusia—Methotrexate—bone cancer	5.89e-05	0.000391	CcSEcCtD
Bortezomib—Connective tissue disorder—Doxorubicin—bone cancer	5.88e-05	0.00039	CcSEcCtD
Bortezomib—Angiopathy—Epirubicin—bone cancer	5.87e-05	0.000389	CcSEcCtD
Bortezomib—Urethral disorder—Doxorubicin—bone cancer	5.87e-05	0.000389	CcSEcCtD
Bortezomib—Immune system disorder—Epirubicin—bone cancer	5.84e-05	0.000387	CcSEcCtD
Bortezomib—Mediastinal disorder—Epirubicin—bone cancer	5.83e-05	0.000386	CcSEcCtD
Bortezomib—Back pain—Methotrexate—bone cancer	5.82e-05	0.000386	CcSEcCtD
Bortezomib—Chills—Epirubicin—bone cancer	5.8e-05	0.000385	CcSEcCtD
Bortezomib—Arrhythmia—Epirubicin—bone cancer	5.78e-05	0.000383	CcSEcCtD
Bortezomib—Visual impairment—Doxorubicin—bone cancer	5.77e-05	0.000382	CcSEcCtD
Bortezomib—Vomiting—Cisplatin—bone cancer	5.69e-05	0.000377	CcSEcCtD
Bortezomib—Vision blurred—Methotrexate—bone cancer	5.67e-05	0.000376	CcSEcCtD
Bortezomib—Mental disorder—Epirubicin—bone cancer	5.67e-05	0.000376	CcSEcCtD
Bortezomib—Erythema multiforme—Doxorubicin—bone cancer	5.66e-05	0.000375	CcSEcCtD
Bortezomib—Rash—Cisplatin—bone cancer	5.64e-05	0.000374	CcSEcCtD
Bortezomib—Dermatitis—Cisplatin—bone cancer	5.64e-05	0.000374	CcSEcCtD
Bortezomib—Erythema—Epirubicin—bone cancer	5.63e-05	0.000373	CcSEcCtD
Bortezomib—Malnutrition—Epirubicin—bone cancer	5.63e-05	0.000373	CcSEcCtD
Bortezomib—Eye disorder—Doxorubicin—bone cancer	5.59e-05	0.000371	CcSEcCtD
Bortezomib—Ill-defined disorder—Methotrexate—bone cancer	5.58e-05	0.00037	CcSEcCtD
Bortezomib—Tinnitus—Doxorubicin—bone cancer	5.58e-05	0.00037	CcSEcCtD
Bortezomib—Anaemia—Methotrexate—bone cancer	5.56e-05	0.000369	CcSEcCtD
Bortezomib—Cardiac disorder—Doxorubicin—bone cancer	5.55e-05	0.000368	CcSEcCtD
Bortezomib—Flushing—Doxorubicin—bone cancer	5.55e-05	0.000368	CcSEcCtD
Bortezomib—Flatulence—Epirubicin—bone cancer	5.55e-05	0.000368	CcSEcCtD
Bortezomib—Dysgeusia—Epirubicin—bone cancer	5.51e-05	0.000366	CcSEcCtD
Bortezomib—Back pain—Epirubicin—bone cancer	5.45e-05	0.000361	CcSEcCtD
Bortezomib—Angiopathy—Doxorubicin—bone cancer	5.43e-05	0.00036	CcSEcCtD
Bortezomib—Malaise—Methotrexate—bone cancer	5.43e-05	0.00036	CcSEcCtD
Bortezomib—Muscle spasms—Epirubicin—bone cancer	5.41e-05	0.000359	CcSEcCtD
Bortezomib—Immune system disorder—Doxorubicin—bone cancer	5.41e-05	0.000358	CcSEcCtD
Bortezomib—Vertigo—Methotrexate—bone cancer	5.41e-05	0.000358	CcSEcCtD
Bortezomib—Mediastinal disorder—Doxorubicin—bone cancer	5.39e-05	0.000358	CcSEcCtD
Bortezomib—Leukopenia—Methotrexate—bone cancer	5.39e-05	0.000357	CcSEcCtD
Bortezomib—Chills—Doxorubicin—bone cancer	5.37e-05	0.000356	CcSEcCtD
Bortezomib—Arrhythmia—Doxorubicin—bone cancer	5.35e-05	0.000354	CcSEcCtD
Bortezomib—Nausea—Cisplatin—bone cancer	5.32e-05	0.000352	CcSEcCtD
Bortezomib—Vision blurred—Epirubicin—bone cancer	5.31e-05	0.000352	CcSEcCtD
Bortezomib—Cough—Methotrexate—bone cancer	5.25e-05	0.000348	CcSEcCtD
Bortezomib—Mental disorder—Doxorubicin—bone cancer	5.24e-05	0.000348	CcSEcCtD
Bortezomib—Ill-defined disorder—Epirubicin—bone cancer	5.22e-05	0.000346	CcSEcCtD
Bortezomib—Convulsion—Methotrexate—bone cancer	5.21e-05	0.000346	CcSEcCtD
Bortezomib—Erythema—Doxorubicin—bone cancer	5.21e-05	0.000345	CcSEcCtD
Bortezomib—Malnutrition—Doxorubicin—bone cancer	5.21e-05	0.000345	CcSEcCtD
Bortezomib—Anaemia—Epirubicin—bone cancer	5.2e-05	0.000345	CcSEcCtD
Bortezomib—Agitation—Epirubicin—bone cancer	5.17e-05	0.000343	CcSEcCtD
Bortezomib—Flatulence—Doxorubicin—bone cancer	5.13e-05	0.00034	CcSEcCtD
Bortezomib—Chest pain—Methotrexate—bone cancer	5.12e-05	0.00034	CcSEcCtD
Bortezomib—Arthralgia—Methotrexate—bone cancer	5.12e-05	0.00034	CcSEcCtD
Bortezomib—Myalgia—Methotrexate—bone cancer	5.12e-05	0.00034	CcSEcCtD
Bortezomib—Dysgeusia—Doxorubicin—bone cancer	5.1e-05	0.000338	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	5.09e-05	0.000337	CcSEcCtD
Bortezomib—Malaise—Epirubicin—bone cancer	5.08e-05	0.000337	CcSEcCtD
Bortezomib—Discomfort—Methotrexate—bone cancer	5.06e-05	0.000336	CcSEcCtD
Bortezomib—Vertigo—Epirubicin—bone cancer	5.06e-05	0.000335	CcSEcCtD
Bortezomib—Syncope—Epirubicin—bone cancer	5.05e-05	0.000335	CcSEcCtD
Bortezomib—Leukopenia—Epirubicin—bone cancer	5.04e-05	0.000334	CcSEcCtD
Bortezomib—Back pain—Doxorubicin—bone cancer	5.04e-05	0.000334	CcSEcCtD
Bortezomib—Muscle spasms—Doxorubicin—bone cancer	5.01e-05	0.000332	CcSEcCtD
Bortezomib—Palpitations—Epirubicin—bone cancer	4.98e-05	0.00033	CcSEcCtD
Bortezomib—Confusional state—Methotrexate—bone cancer	4.95e-05	0.000328	CcSEcCtD
Bortezomib—Loss of consciousness—Epirubicin—bone cancer	4.95e-05	0.000328	CcSEcCtD
Bortezomib—Cough—Epirubicin—bone cancer	4.91e-05	0.000326	CcSEcCtD
Bortezomib—Anaphylactic shock—Methotrexate—bone cancer	4.91e-05	0.000326	CcSEcCtD
Bortezomib—Vision blurred—Doxorubicin—bone cancer	4.91e-05	0.000325	CcSEcCtD
Bortezomib—Convulsion—Epirubicin—bone cancer	4.88e-05	0.000323	CcSEcCtD
Bortezomib—Infection—Methotrexate—bone cancer	4.88e-05	0.000323	CcSEcCtD
Bortezomib—Hypertension—Epirubicin—bone cancer	4.86e-05	0.000322	CcSEcCtD
Bortezomib—Ill-defined disorder—Doxorubicin—bone cancer	4.83e-05	0.00032	CcSEcCtD
Bortezomib—Nervous system disorder—Methotrexate—bone cancer	4.82e-05	0.000319	CcSEcCtD
Bortezomib—Anaemia—Doxorubicin—bone cancer	4.82e-05	0.000319	CcSEcCtD
Bortezomib—Thrombocytopenia—Methotrexate—bone cancer	4.81e-05	0.000319	CcSEcCtD
Bortezomib—Arthralgia—Epirubicin—bone cancer	4.79e-05	0.000318	CcSEcCtD
Bortezomib—Myalgia—Epirubicin—bone cancer	4.79e-05	0.000318	CcSEcCtD
Bortezomib—Chest pain—Epirubicin—bone cancer	4.79e-05	0.000318	CcSEcCtD
Bortezomib—Agitation—Doxorubicin—bone cancer	4.79e-05	0.000317	CcSEcCtD
Bortezomib—Anxiety—Epirubicin—bone cancer	4.78e-05	0.000317	CcSEcCtD
Bortezomib—Skin disorder—Methotrexate—bone cancer	4.77e-05	0.000316	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	4.76e-05	0.000316	CcSEcCtD
Bortezomib—Hyperhidrosis—Methotrexate—bone cancer	4.75e-05	0.000315	CcSEcCtD
Bortezomib—Discomfort—Epirubicin—bone cancer	4.74e-05	0.000314	CcSEcCtD
Bortezomib—Malaise—Doxorubicin—bone cancer	4.7e-05	0.000311	CcSEcCtD
Bortezomib—Vertigo—Doxorubicin—bone cancer	4.68e-05	0.00031	CcSEcCtD
Bortezomib—Anorexia—Methotrexate—bone cancer	4.68e-05	0.00031	CcSEcCtD
Bortezomib—Syncope—Doxorubicin—bone cancer	4.67e-05	0.00031	CcSEcCtD
Bortezomib—Leukopenia—Doxorubicin—bone cancer	4.66e-05	0.000309	CcSEcCtD
Bortezomib—Confusional state—Epirubicin—bone cancer	4.63e-05	0.000307	CcSEcCtD
Bortezomib—Palpitations—Doxorubicin—bone cancer	4.6e-05	0.000305	CcSEcCtD
Bortezomib—Anaphylactic shock—Epirubicin—bone cancer	4.6e-05	0.000305	CcSEcCtD
Bortezomib—Oedema—Epirubicin—bone cancer	4.6e-05	0.000305	CcSEcCtD
Bortezomib—Hypotension—Methotrexate—bone cancer	4.59e-05	0.000304	CcSEcCtD
Bortezomib—Loss of consciousness—Doxorubicin—bone cancer	4.58e-05	0.000304	CcSEcCtD
Bortezomib—Infection—Epirubicin—bone cancer	4.57e-05	0.000303	CcSEcCtD
Bortezomib—Cough—Doxorubicin—bone cancer	4.55e-05	0.000301	CcSEcCtD
Bortezomib—Shock—Epirubicin—bone cancer	4.52e-05	0.0003	CcSEcCtD
Bortezomib—Convulsion—Doxorubicin—bone cancer	4.51e-05	0.000299	CcSEcCtD
Bortezomib—Nervous system disorder—Epirubicin—bone cancer	4.51e-05	0.000299	CcSEcCtD
Bortezomib—Thrombocytopenia—Epirubicin—bone cancer	4.5e-05	0.000298	CcSEcCtD
Bortezomib—Hypertension—Doxorubicin—bone cancer	4.5e-05	0.000298	CcSEcCtD
Bortezomib—Tachycardia—Epirubicin—bone cancer	4.48e-05	0.000297	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Methotrexate—bone cancer	4.47e-05	0.000297	CcSEcCtD
Bortezomib—Skin disorder—Epirubicin—bone cancer	4.46e-05	0.000296	CcSEcCtD
Bortezomib—Hyperhidrosis—Epirubicin—bone cancer	4.44e-05	0.000294	CcSEcCtD
Bortezomib—Insomnia—Methotrexate—bone cancer	4.44e-05	0.000294	CcSEcCtD
Bortezomib—Myalgia—Doxorubicin—bone cancer	4.44e-05	0.000294	CcSEcCtD
Bortezomib—Arthralgia—Doxorubicin—bone cancer	4.44e-05	0.000294	CcSEcCtD
Bortezomib—Chest pain—Doxorubicin—bone cancer	4.44e-05	0.000294	CcSEcCtD
Bortezomib—Anxiety—Doxorubicin—bone cancer	4.42e-05	0.000293	CcSEcCtD
Bortezomib—Paraesthesia—Methotrexate—bone cancer	4.41e-05	0.000292	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	4.4e-05	0.000292	CcSEcCtD
Bortezomib—Discomfort—Doxorubicin—bone cancer	4.38e-05	0.000291	CcSEcCtD
Bortezomib—Anorexia—Epirubicin—bone cancer	4.38e-05	0.00029	CcSEcCtD
Bortezomib—Dyspnoea—Methotrexate—bone cancer	4.38e-05	0.00029	CcSEcCtD
Bortezomib—Dyspepsia—Methotrexate—bone cancer	4.32e-05	0.000287	CcSEcCtD
Bortezomib—Hypotension—Epirubicin—bone cancer	4.29e-05	0.000285	CcSEcCtD
Bortezomib—Confusional state—Doxorubicin—bone cancer	4.29e-05	0.000284	CcSEcCtD
Bortezomib—Decreased appetite—Methotrexate—bone cancer	4.27e-05	0.000283	CcSEcCtD
Bortezomib—Oedema—Doxorubicin—bone cancer	4.25e-05	0.000282	CcSEcCtD
Bortezomib—Anaphylactic shock—Doxorubicin—bone cancer	4.25e-05	0.000282	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Methotrexate—bone cancer	4.24e-05	0.000281	CcSEcCtD
Bortezomib—Fatigue—Methotrexate—bone cancer	4.23e-05	0.000281	CcSEcCtD
Bortezomib—Infection—Doxorubicin—bone cancer	4.22e-05	0.00028	CcSEcCtD
Bortezomib—Pain—Methotrexate—bone cancer	4.2e-05	0.000278	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Epirubicin—bone cancer	4.19e-05	0.000278	CcSEcCtD
Bortezomib—Shock—Doxorubicin—bone cancer	4.18e-05	0.000277	CcSEcCtD
Bortezomib—Nervous system disorder—Doxorubicin—bone cancer	4.17e-05	0.000276	CcSEcCtD
Bortezomib—Thrombocytopenia—Doxorubicin—bone cancer	4.16e-05	0.000276	CcSEcCtD
Bortezomib—Insomnia—Epirubicin—bone cancer	4.16e-05	0.000276	CcSEcCtD
Bortezomib—Tachycardia—Doxorubicin—bone cancer	4.15e-05	0.000275	CcSEcCtD
Bortezomib—Skin disorder—Doxorubicin—bone cancer	4.13e-05	0.000274	CcSEcCtD
Bortezomib—Paraesthesia—Epirubicin—bone cancer	4.13e-05	0.000274	CcSEcCtD
Bortezomib—Hyperhidrosis—Doxorubicin—bone cancer	4.11e-05	0.000272	CcSEcCtD
Bortezomib—Dyspnoea—Epirubicin—bone cancer	4.1e-05	0.000272	CcSEcCtD
Bortezomib—Anorexia—Doxorubicin—bone cancer	4.05e-05	0.000269	CcSEcCtD
Bortezomib—Feeling abnormal—Methotrexate—bone cancer	4.05e-05	0.000268	CcSEcCtD
Bortezomib—Dyspepsia—Epirubicin—bone cancer	4.05e-05	0.000268	CcSEcCtD
Bortezomib—Gastrointestinal pain—Methotrexate—bone cancer	4.02e-05	0.000266	CcSEcCtD
Bortezomib—Decreased appetite—Epirubicin—bone cancer	3.99e-05	0.000265	CcSEcCtD
Bortezomib—Hypotension—Doxorubicin—bone cancer	3.97e-05	0.000263	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Epirubicin—bone cancer	3.97e-05	0.000263	CcSEcCtD
Bortezomib—Fatigue—Epirubicin—bone cancer	3.96e-05	0.000263	CcSEcCtD
Bortezomib—Pain—Epirubicin—bone cancer	3.93e-05	0.000261	CcSEcCtD
Bortezomib—Constipation—Epirubicin—bone cancer	3.93e-05	0.000261	CcSEcCtD
Bortezomib—Urticaria—Methotrexate—bone cancer	3.9e-05	0.000259	CcSEcCtD
Bortezomib—Abdominal pain—Methotrexate—bone cancer	3.88e-05	0.000257	CcSEcCtD
Bortezomib—Body temperature increased—Methotrexate—bone cancer	3.88e-05	0.000257	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Doxorubicin—bone cancer	3.87e-05	0.000257	CcSEcCtD
Bortezomib—Insomnia—Doxorubicin—bone cancer	3.85e-05	0.000255	CcSEcCtD
Bortezomib—Paraesthesia—Doxorubicin—bone cancer	3.82e-05	0.000253	CcSEcCtD
Bortezomib—Dyspnoea—Doxorubicin—bone cancer	3.79e-05	0.000251	CcSEcCtD
Bortezomib—Feeling abnormal—Epirubicin—bone cancer	3.79e-05	0.000251	CcSEcCtD
Bortezomib—Gastrointestinal pain—Epirubicin—bone cancer	3.76e-05	0.000249	CcSEcCtD
Bortezomib—Dyspepsia—Doxorubicin—bone cancer	3.74e-05	0.000248	CcSEcCtD
Bortezomib—Decreased appetite—Doxorubicin—bone cancer	3.7e-05	0.000245	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Doxorubicin—bone cancer	3.67e-05	0.000243	CcSEcCtD
Bortezomib—Fatigue—Doxorubicin—bone cancer	3.67e-05	0.000243	CcSEcCtD
Bortezomib—Urticaria—Epirubicin—bone cancer	3.65e-05	0.000242	CcSEcCtD
Bortezomib—Pain—Doxorubicin—bone cancer	3.64e-05	0.000241	CcSEcCtD
Bortezomib—Constipation—Doxorubicin—bone cancer	3.64e-05	0.000241	CcSEcCtD
Bortezomib—Abdominal pain—Epirubicin—bone cancer	3.63e-05	0.000241	CcSEcCtD
Bortezomib—Body temperature increased—Epirubicin—bone cancer	3.63e-05	0.000241	CcSEcCtD
Bortezomib—Hypersensitivity—Methotrexate—bone cancer	3.62e-05	0.00024	CcSEcCtD
Bortezomib—Asthenia—Methotrexate—bone cancer	3.52e-05	0.000234	CcSEcCtD
Bortezomib—Feeling abnormal—Doxorubicin—bone cancer	3.5e-05	0.000232	CcSEcCtD
Bortezomib—Gastrointestinal pain—Doxorubicin—bone cancer	3.48e-05	0.00023	CcSEcCtD
Bortezomib—Pruritus—Methotrexate—bone cancer	3.47e-05	0.00023	CcSEcCtD
Bortezomib—Hypersensitivity—Epirubicin—bone cancer	3.39e-05	0.000224	CcSEcCtD
Bortezomib—Urticaria—Doxorubicin—bone cancer	3.38e-05	0.000224	CcSEcCtD
Bortezomib—Abdominal pain—Doxorubicin—bone cancer	3.36e-05	0.000223	CcSEcCtD
Bortezomib—Body temperature increased—Doxorubicin—bone cancer	3.36e-05	0.000223	CcSEcCtD
Bortezomib—Diarrhoea—Methotrexate—bone cancer	3.36e-05	0.000223	CcSEcCtD
Bortezomib—Asthenia—Epirubicin—bone cancer	3.3e-05	0.000219	CcSEcCtD
Bortezomib—Pruritus—Epirubicin—bone cancer	3.25e-05	0.000216	CcSEcCtD
Bortezomib—Dizziness—Methotrexate—bone cancer	3.25e-05	0.000215	CcSEcCtD
Bortezomib—Diarrhoea—Epirubicin—bone cancer	3.14e-05	0.000208	CcSEcCtD
Bortezomib—Hypersensitivity—Doxorubicin—bone cancer	3.13e-05	0.000208	CcSEcCtD
Bortezomib—Vomiting—Methotrexate—bone cancer	3.12e-05	0.000207	CcSEcCtD
Bortezomib—Rash—Methotrexate—bone cancer	3.1e-05	0.000205	CcSEcCtD
Bortezomib—Dermatitis—Methotrexate—bone cancer	3.09e-05	0.000205	CcSEcCtD
Bortezomib—Headache—Methotrexate—bone cancer	3.08e-05	0.000204	CcSEcCtD
Bortezomib—Asthenia—Doxorubicin—bone cancer	3.05e-05	0.000202	CcSEcCtD
Bortezomib—Dizziness—Epirubicin—bone cancer	3.04e-05	0.000201	CcSEcCtD
Bortezomib—Pruritus—Doxorubicin—bone cancer	3.01e-05	0.000199	CcSEcCtD
Bortezomib—Vomiting—Epirubicin—bone cancer	2.92e-05	0.000194	CcSEcCtD
Bortezomib—Nausea—Methotrexate—bone cancer	2.92e-05	0.000193	CcSEcCtD
Bortezomib—Diarrhoea—Doxorubicin—bone cancer	2.91e-05	0.000193	CcSEcCtD
Bortezomib—Rash—Epirubicin—bone cancer	2.9e-05	0.000192	CcSEcCtD
Bortezomib—Dermatitis—Epirubicin—bone cancer	2.89e-05	0.000192	CcSEcCtD
Bortezomib—Headache—Epirubicin—bone cancer	2.88e-05	0.000191	CcSEcCtD
Bortezomib—Dizziness—Doxorubicin—bone cancer	2.81e-05	0.000186	CcSEcCtD
Bortezomib—Nausea—Epirubicin—bone cancer	2.73e-05	0.000181	CcSEcCtD
Bortezomib—Vomiting—Doxorubicin—bone cancer	2.7e-05	0.000179	CcSEcCtD
Bortezomib—Rash—Doxorubicin—bone cancer	2.68e-05	0.000178	CcSEcCtD
Bortezomib—Dermatitis—Doxorubicin—bone cancer	2.68e-05	0.000178	CcSEcCtD
Bortezomib—Headache—Doxorubicin—bone cancer	2.66e-05	0.000177	CcSEcCtD
Bortezomib—Nausea—Doxorubicin—bone cancer	2.53e-05	0.000167	CcSEcCtD
Bortezomib—PSMB5—Cell Cycle—MDM2—bone cancer	2.42e-05	0.000221	CbGpPWpGaD
Bortezomib—PSMB1—Cell Cycle—MDM2—bone cancer	2.42e-05	0.000221	CbGpPWpGaD
Bortezomib—PSMB2—Cell Cycle—MDM2—bone cancer	2.42e-05	0.000221	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—NT5C3A—bone cancer	2.42e-05	0.000221	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—NDUFA12—bone cancer	2.39e-05	0.000218	CbGpPWpGaD
Bortezomib—PSMB8—Cell Cycle—MDM2—bone cancer	2.39e-05	0.000217	CbGpPWpGaD
Bortezomib—PSMB5—Disease—TGFBR2—bone cancer	2.31e-05	0.000211	CbGpPWpGaD
Bortezomib—PSMB2—Disease—TGFBR2—bone cancer	2.31e-05	0.000211	CbGpPWpGaD
Bortezomib—PSMB1—Disease—TGFBR2—bone cancer	2.31e-05	0.000211	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—SMO—bone cancer	2.29e-05	0.000208	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—SMO—bone cancer	2.29e-05	0.000208	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—SMO—bone cancer	2.29e-05	0.000208	CbGpPWpGaD
Bortezomib—PSMB8—Disease—TGFBR2—bone cancer	2.28e-05	0.000208	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—CYP3A4—bone cancer	2.27e-05	0.000206	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—CYP3A4—bone cancer	2.27e-05	0.000206	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—CYP3A4—bone cancer	2.27e-05	0.000206	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—KIT—bone cancer	2.26e-05	0.000205	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—SMO—bone cancer	2.25e-05	0.000205	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—KIT—bone cancer	2.25e-05	0.000204	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—KIT—bone cancer	2.24e-05	0.000203	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—CYP3A4—bone cancer	2.23e-05	0.000203	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—NT5C3A—bone cancer	2.22e-05	0.000202	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—MDM2—bone cancer	2.22e-05	0.000202	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—MDM2—bone cancer	2.22e-05	0.000202	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—MDM2—bone cancer	2.22e-05	0.000202	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—NDUFA12—bone cancer	2.2e-05	0.0002	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—MDM2—bone cancer	2.19e-05	0.000199	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—NDUFA12—bone cancer	2.18e-05	0.000199	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TGFBR2—bone cancer	2.14e-05	0.000195	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TGFBR2—bone cancer	2.13e-05	0.000194	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TGFBR2—bone cancer	2.12e-05	0.000193	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—GNA11—bone cancer	2.09e-05	0.00019	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—GNA11—bone cancer	2.09e-05	0.00019	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—GNA11—bone cancer	2.09e-05	0.00019	CbGpPWpGaD
Bortezomib—PSMA1—Disease—KIT—bone cancer	2.08e-05	0.00019	CbGpPWpGaD
Bortezomib—PSMD1—Disease—KIT—bone cancer	2.07e-05	0.000189	CbGpPWpGaD
Bortezomib—PSMD2—Disease—KIT—bone cancer	2.06e-05	0.000188	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—GNA11—bone cancer	2.06e-05	0.000188	CbGpPWpGaD
Bortezomib—CYP3A4—Biological oxidations—GSTP1—bone cancer	2.05e-05	0.000187	CbGpPWpGaD
Bortezomib—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	2.03e-05	0.000184	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—IGF1R—bone cancer	2.01e-05	0.000183	CbGpPWpGaD
Bortezomib—PSMA1—Adaptive Immune System—EGFR—bone cancer	2e-05	0.000182	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—IGF1R—bone cancer	2e-05	0.000182	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—EGFR—bone cancer	1.99e-05	0.000181	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—IGF1R—bone cancer	1.99e-05	0.000181	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—NT5C3A—bone cancer	1.98e-05	0.000181	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—EGFR—bone cancer	1.98e-05	0.00018	CbGpPWpGaD
Bortezomib—PSMA1—Disease—BRAF—bone cancer	1.96e-05	0.000178	CbGpPWpGaD
Bortezomib—PSMD1—Disease—BRAF—bone cancer	1.95e-05	0.000177	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—ATF1—bone cancer	1.94e-05	0.000177	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—ATF1—bone cancer	1.94e-05	0.000177	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—ATF1—bone cancer	1.94e-05	0.000177	CbGpPWpGaD
Bortezomib—PSMD2—Disease—BRAF—bone cancer	1.94e-05	0.000177	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—GSTP1—bone cancer	1.94e-05	0.000176	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—GSTP1—bone cancer	1.94e-05	0.000176	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—GSTP1—bone cancer	1.94e-05	0.000176	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—ATF1—bone cancer	1.92e-05	0.000174	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—GSTP1—bone cancer	1.91e-05	0.000174	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IL3—bone cancer	1.89e-05	0.000172	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IL3—bone cancer	1.89e-05	0.000172	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IL3—bone cancer	1.89e-05	0.000172	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IL3—bone cancer	1.87e-05	0.00017	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—NDUFA12—bone cancer	1.87e-05	0.00017	CbGpPWpGaD
Bortezomib—PSMA1—Cell Cycle—TP53—bone cancer	1.84e-05	0.000167	CbGpPWpGaD
Bortezomib—PSMD1—Cell Cycle—TP53—bone cancer	1.83e-05	0.000166	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—NT5C3A—bone cancer	1.82e-05	0.000166	CbGpPWpGaD
Bortezomib—PSMD2—Cell Cycle—TP53—bone cancer	1.82e-05	0.000165	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—NT5C3A—bone cancer	1.81e-05	0.000165	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—MDM2—bone cancer	1.78e-05	0.000162	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—MDM2—bone cancer	1.77e-05	0.000161	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—MDM2—bone cancer	1.76e-05	0.00016	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—KIT—bone cancer	1.71e-05	0.000156	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—KIT—bone cancer	1.71e-05	0.000156	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—KIT—bone cancer	1.71e-05	0.000156	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—KIT—bone cancer	1.69e-05	0.000153	CbGpPWpGaD
Bortezomib—PSMA1—Disease—MDM2—bone cancer	1.64e-05	0.000149	CbGpPWpGaD
Bortezomib—PSMD1—Disease—MDM2—bone cancer	1.63e-05	0.000149	CbGpPWpGaD
Bortezomib—PSMD2—Disease—MDM2—bone cancer	1.63e-05	0.000148	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TGFBR2—bone cancer	1.62e-05	0.000147	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TGFBR2—bone cancer	1.62e-05	0.000147	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TGFBR2—bone cancer	1.62e-05	0.000147	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TGFBR2—bone cancer	1.6e-05	0.000145	CbGpPWpGaD
Bortezomib—PSMA1—Disease—PTGS2—bone cancer	1.58e-05	0.000144	CbGpPWpGaD
Bortezomib—PSMB5—Disease—KIT—bone cancer	1.58e-05	0.000144	CbGpPWpGaD
Bortezomib—PSMB1—Disease—KIT—bone cancer	1.58e-05	0.000144	CbGpPWpGaD
Bortezomib—PSMB2—Disease—KIT—bone cancer	1.58e-05	0.000144	CbGpPWpGaD
Bortezomib—PSMD1—Disease—PTGS2—bone cancer	1.57e-05	0.000143	CbGpPWpGaD
Bortezomib—PSMD2—Disease—PTGS2—bone cancer	1.57e-05	0.000143	CbGpPWpGaD
Bortezomib—PSMB8—Disease—KIT—bone cancer	1.56e-05	0.000142	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—NT5C3A—bone cancer	1.55e-05	0.000141	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—JUN—bone cancer	1.54e-05	0.000141	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—JUN—bone cancer	1.54e-05	0.00014	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—JUN—bone cancer	1.53e-05	0.000139	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IGF1R—bone cancer	1.52e-05	0.000139	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IGF1R—bone cancer	1.52e-05	0.000139	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IGF1R—bone cancer	1.52e-05	0.000139	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—EGFR—bone cancer	1.52e-05	0.000138	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—EGFR—bone cancer	1.52e-05	0.000138	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—EGFR—bone cancer	1.52e-05	0.000138	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—ENO2—bone cancer	1.51e-05	0.000137	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IGF1R—bone cancer	1.5e-05	0.000137	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—EGFR—bone cancer	1.5e-05	0.000136	CbGpPWpGaD
Bortezomib—PSMB2—Disease—BRAF—bone cancer	1.48e-05	0.000135	CbGpPWpGaD
Bortezomib—PSMB1—Disease—BRAF—bone cancer	1.48e-05	0.000135	CbGpPWpGaD
Bortezomib—PSMB5—Disease—BRAF—bone cancer	1.48e-05	0.000135	CbGpPWpGaD
Bortezomib—PSMB8—Disease—BRAF—bone cancer	1.46e-05	0.000133	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—KIT—bone cancer	1.46e-05	0.000133	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—KIT—bone cancer	1.45e-05	0.000132	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—KIT—bone cancer	1.45e-05	0.000132	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—NDUFA12—bone cancer	1.44e-05	0.000131	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—DHFR—bone cancer	1.4e-05	0.000127	CbGpPWpGaD
Bortezomib—PSMB5—Cell Cycle—TP53—bone cancer	1.39e-05	0.000127	CbGpPWpGaD
Bortezomib—PSMB1—Cell Cycle—TP53—bone cancer	1.39e-05	0.000127	CbGpPWpGaD
Bortezomib—PSMB2—Cell Cycle—TP53—bone cancer	1.39e-05	0.000127	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—BRAF—bone cancer	1.37e-05	0.000125	CbGpPWpGaD
Bortezomib—PSMB8—Cell Cycle—TP53—bone cancer	1.37e-05	0.000125	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—BRAF—bone cancer	1.36e-05	0.000124	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—BRAF—bone cancer	1.36e-05	0.000124	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—MDM2—bone cancer	1.35e-05	0.000123	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—MDM2—bone cancer	1.35e-05	0.000123	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—MDM2—bone cancer	1.35e-05	0.000123	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—MDM2—bone cancer	1.33e-05	0.000121	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—PTGS2—bone cancer	1.32e-05	0.000121	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—PTGS2—bone cancer	1.32e-05	0.00012	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—PTGS2—bone cancer	1.31e-05	0.000119	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—GNA11—bone cancer	1.31e-05	0.000119	CbGpPWpGaD
Bortezomib—PSMB1—Disease—MDM2—bone cancer	1.24e-05	0.000113	CbGpPWpGaD
Bortezomib—PSMB5—Disease—MDM2—bone cancer	1.24e-05	0.000113	CbGpPWpGaD
Bortezomib—PSMB2—Disease—MDM2—bone cancer	1.24e-05	0.000113	CbGpPWpGaD
Bortezomib—PSMB8—Disease—MDM2—bone cancer	1.23e-05	0.000112	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—EGFR—bone cancer	1.21e-05	0.000111	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—EGFR—bone cancer	1.21e-05	0.00011	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—EGFR—bone cancer	1.2e-05	0.000109	CbGpPWpGaD
Bortezomib—PSMB5—Disease—PTGS2—bone cancer	1.2e-05	0.000109	CbGpPWpGaD
Bortezomib—PSMB1—Disease—PTGS2—bone cancer	1.2e-05	0.000109	CbGpPWpGaD
Bortezomib—PSMB2—Disease—PTGS2—bone cancer	1.2e-05	0.000109	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—NT5C3A—bone cancer	1.19e-05	0.000109	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—CYP3A4—bone cancer	1.18e-05	0.000108	CbGpPWpGaD
Bortezomib—PSMB8—Disease—PTGS2—bone cancer	1.18e-05	0.000108	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.18e-05	0.000107	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—JUN—bone cancer	1.17e-05	0.000107	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—JUN—bone cancer	1.17e-05	0.000107	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—JUN—bone cancer	1.17e-05	0.000107	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—JUN—bone cancer	1.15e-05	0.000105	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—MDM2—bone cancer	1.15e-05	0.000105	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—MDM2—bone cancer	1.14e-05	0.000104	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—MDM2—bone cancer	1.14e-05	0.000104	CbGpPWpGaD
Bortezomib—PSMA1—Disease—EGFR—bone cancer	1.12e-05	0.000102	CbGpPWpGaD
Bortezomib—PSMD1—Disease—EGFR—bone cancer	1.12e-05	0.000102	CbGpPWpGaD
Bortezomib—PSMD2—Disease—EGFR—bone cancer	1.11e-05	0.000101	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—KIT—bone cancer	1.11e-05	0.000101	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—KIT—bone cancer	1.11e-05	0.000101	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—KIT—bone cancer	1.11e-05	0.000101	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—KIT—bone cancer	1.09e-05	9.92e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ENO2—bone cancer	1.06e-05	9.66e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—BRAF—bone cancer	1.04e-05	9.46e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—BRAF—bone cancer	1.04e-05	9.46e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—BRAF—bone cancer	1.04e-05	9.46e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—BRAF—bone cancer	1.02e-05	9.32e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—GSTP1—bone cancer	1.01e-05	9.22e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—PTGS2—bone cancer	1e-05	9.14e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—PTGS2—bone cancer	1e-05	9.14e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—PTGS2—bone cancer	1e-05	9.14e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—JUN—bone cancer	9.99e-06	9.09e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—JUN—bone cancer	9.94e-06	9.05e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—PTGS2—bone cancer	9.9e-06	9.01e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—JUN—bone cancer	9.89e-06	9e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—DHFR—bone cancer	9.85e-06	8.96e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ENO2—bone cancer	9.73e-06	8.86e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—MMP9—bone cancer	9.72e-06	8.84e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—MMP9—bone cancer	9.67e-06	8.8e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—MMP9—bone cancer	9.63e-06	8.76e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—GNA11—bone cancer	9.21e-06	8.38e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—EGFR—bone cancer	9.2e-06	8.38e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—EGFR—bone cancer	9.2e-06	8.38e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—EGFR—bone cancer	9.2e-06	8.38e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—EGFR—bone cancer	9.07e-06	8.26e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—DHFR—bone cancer	9.03e-06	8.22e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MDM2—bone cancer	8.71e-06	7.92e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MDM2—bone cancer	8.71e-06	7.92e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MDM2—bone cancer	8.71e-06	7.92e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ENO2—bone cancer	8.69e-06	7.91e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MDM2—bone cancer	8.59e-06	7.81e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—EGFR—bone cancer	8.5e-06	7.73e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—EGFR—bone cancer	8.5e-06	7.73e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—EGFR—bone cancer	8.5e-06	7.73e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GNA11—bone cancer	8.44e-06	7.68e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—EGFR—bone cancer	8.38e-06	7.62e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—CYP3A4—bone cancer	8.35e-06	7.6e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	8.3e-06	7.56e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—DHFR—bone cancer	8.06e-06	7.34e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ENO2—bone cancer	7.99e-06	7.27e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ENO2—bone cancer	7.92e-06	7.21e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—EGFR—bone cancer	7.85e-06	7.15e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—EGFR—bone cancer	7.82e-06	7.11e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—EGFR—bone cancer	7.78e-06	7.08e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CYP3A4—bone cancer	7.65e-06	6.96e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	7.61e-06	6.93e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—JUN—bone cancer	7.57e-06	6.89e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—JUN—bone cancer	7.57e-06	6.89e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—JUN—bone cancer	7.57e-06	6.89e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GNA11—bone cancer	7.53e-06	6.86e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—JUN—bone cancer	7.46e-06	6.79e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—DHFR—bone cancer	7.41e-06	6.75e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MMP9—bone cancer	7.36e-06	6.7e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MMP9—bone cancer	7.36e-06	6.7e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MMP9—bone cancer	7.36e-06	6.7e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—DHFR—bone cancer	7.35e-06	6.69e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MMP9—bone cancer	7.26e-06	6.61e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—GSTP1—bone cancer	7.14e-06	6.5e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GNA11—bone cancer	6.93e-06	6.31e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GNA11—bone cancer	6.87e-06	6.25e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CYP3A4—bone cancer	6.83e-06	6.22e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	6.8e-06	6.18e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ENO2—bone cancer	6.77e-06	6.16e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TP53—bone cancer	6.59e-06	6e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TP53—bone cancer	6.56e-06	5.97e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GSTP1—bone cancer	6.54e-06	5.96e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TP53—bone cancer	6.53e-06	5.94e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CYP3A4—bone cancer	6.28e-06	5.72e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—DHFR—bone cancer	6.28e-06	5.72e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CYP3A4—bone cancer	6.23e-06	5.67e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	6.2e-06	5.64e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—EGFR—bone cancer	5.95e-06	5.42e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—EGFR—bone cancer	5.95e-06	5.42e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—EGFR—bone cancer	5.95e-06	5.42e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GNA11—bone cancer	5.87e-06	5.34e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—EGFR—bone cancer	5.87e-06	5.34e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GSTP1—bone cancer	5.84e-06	5.32e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GSTP1—bone cancer	5.37e-06	4.89e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GSTP1—bone cancer	5.33e-06	4.85e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CYP3A4—bone cancer	5.32e-06	4.84e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	5.29e-06	4.82e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PTGS2—bone cancer	5.25e-06	4.78e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ENO2—bone cancer	5.22e-06	4.75e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TP53—bone cancer	5e-06	4.55e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TP53—bone cancer	5e-06	4.55e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TP53—bone cancer	5e-06	4.55e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TP53—bone cancer	4.93e-06	4.48e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—DHFR—bone cancer	4.85e-06	4.41e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GSTP1—bone cancer	4.55e-06	4.14e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GNA11—bone cancer	4.53e-06	4.12e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PTGS2—bone cancer	3.7e-06	3.37e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSTP1—bone cancer	3.51e-06	3.2e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PTGS2—bone cancer	3.39e-06	3.09e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PTGS2—bone cancer	3.03e-06	2.75e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PTGS2—bone cancer	2.78e-06	2.53e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PTGS2—bone cancer	2.76e-06	2.51e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PTGS2—bone cancer	2.36e-06	2.15e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTGS2—bone cancer	1.82e-06	1.66e-05	CbGpPWpGaD
